PBAC's latest decision on Lenalidomide: Recommended with restriction (2023). Considered for Treatment of newly diagnosed multiple myeloma (as monotherapy, doublet therapy, or triplet therapy), progressive multiple myeloma, relapsed/refractory multiple myeloma (including triple combination therapy with elotuzumab or carfilzomib), and myelodysplastic syndrome.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
15
first 2008
PBS spend
$85M
47,638 scripts · 2024
Eligible population
Patients with newly diagnosed multiple myeloma (NDMM), progressive multiple myeloma, relapsed/refractory multiple myeloma (RRMM), and myelodysplastic syndrome requiring lenalidomide therapy in various treatment combinations (monotherapy, doublet, or triplet therapy).
$15k/QALY–$45k/QALY across 7 submissions (2008–2019) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
PBS expenditure
The Australian government paid $85M in PBS benefits for Lenalidomide in 2024 across 47,638 scripts, at $1,773 per script.
Submission history
Mar 2008: Not recommended · Restricted — ICER $105k/QALY
Nov 2008: Recommended with restriction · Restricted
Mar 2011: Not recommended — ICER $75k/QALY
Jul 2011: Not recommended — ICER $75k/QALY
Mar 2013: Recommended with restriction · Authority Required — ICER $45k/QALY
Nov 2015: Recommended with restriction · Authority Required — ICER $200k/QALY
Mar 2016: Recommended with restriction · Restricted — ICER $105k/QALY
Jul 2016: Recommended with restriction · Authority Required
Nov 2017: Recommended · Restricted
Mar 2018: Recommended with restriction · Authority Required
Mar 2019: Recommended with restriction · Restricted
Mar 2019: Not recommended · Authority Required
Jul 2019: Deferred · Restricted — ICER $45k/QALY
Aug 2019: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required